STRO vs STT · rev $62.0M vs P/E 17, $45.02B cap
Sutro Biopharma (STRO) versus State Street Corp (STT) — a side-by-side from cached financials, not a winner call.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
State Street Corp (STT) is a asset management company listed on US.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
STT does not have a complete income-statement cache yet.
STRO currently screens at market cap $470.8M. STT currently screens at market cap $45.02B and trailing P/E 16.5.
Not investment advice. Open the STRO and STT stock pages for the full models.
Not investment advice.